Circumventing Doxorubicin Resistance Using Elastin-like Polypeptide Biopolymer-Mediated Drug Delivery
Although doxorubicin (dox), an anthracycline antibiotic, is widely used and effective in treating cancer, its treatment efficiency is limited by low blood plasma solubility, poor pharmacokinetics, and adverse side effects, including irreversible cardiotoxicity. Moreover, cancer cells often develop d...
Main Authors: | Sonja Dragojevic, Lindsay Turner, Drazen Raucher |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-02-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/23/4/2301 |
Similar Items
-
Elastin-like Polypeptide Hydrogels for Tunable, Sustained Local Chemotherapy in Malignant Glioma
by: Sonja Dragojevic, et al.
Published: (2022-09-01) -
Targeted Drug Delivery Biopolymers Effectively Inhibit Breast Tumor Growth and Prevent Doxorubicin-Induced Cardiotoxicity
by: Sonja Dragojevic, et al.
Published: (2022-05-01) -
Cell-Penetrating Doxorubicin Released from Elastin-Like Polypeptide Kills Doxorubicin-Resistant Cancer Cells in In Vitro Study
by: Jung Su Ryu, et al.
Published: (2021-01-01) -
The construction of elastin-like polypeptides and their applications in drug delivery system and tissue repair
by: Yingshu Guo, et al.
Published: (2023-11-01) -
Application of Thermally Responsive Elastin-like Polypeptide Fused to a Lactoferrin-derived Peptide for Treatment of Pancreatic Cancer
by: Emily Thomas, et al.
Published: (2009-06-01)